Lisa H. Butterfield

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +13

Induction of CD8⁺T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma

Hideho Okada, Paweł Kaliński, Ryo Ueda et al. · Journal of Clinical Oncology · 2010 · 563 citations · Full text

Medicine, Immunology, Oncology +17

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

Ahmad A. Tarhini, Haris Zahoor, Yan Lin et al. · Journal for ImmunoTherapy of Cancer · 2015 · 390 citations · Full text

Life Sciences, Immunology, Oncology +17

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

Jun Zhou, Kathleen M. Mahoney, Anita Giobbie‐Hurder et al. · Cancer Immunology Research · 2017 · 362 citations · Full text

Life Sciences, Immunology, Oncology +17

Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma

F. Stephen Hodi, David F. McDermott, Uma N. M. Rao et al. · JAMA · 2014 · 355 citations

Medicine, Oncology, Pharmacotherapy +17